OrbiMed Advisors LLC
Investment Details
Investor Type
Private Investment Firm
Asset Class Focus
Private Equity, Venture Capital, Public Equity, Royalty and Credit Funds, Private Credit, Royalty/Credit Funds
Stage Focus
Seed, Early Stage, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, United Kingdom, Canada, Germany, Hong Kong, Japan, Australia, Singapore, China, India, Brazil, France, Italy, Spain, Mexico, South Korea, Saudi Arabia, South Africa, Russia, Israel
Industries Focus
- Healthcare Services
- Digital Health
- Medical Devices
- Diagnostics
- Biotechnology
- Medical Technology
- Healthcare Equipment
- Healthcare IT
- Biopharmaceuticals
- Healthcare Supplies
- Healthcare Distribution
- Healthcare Consulting
- Healthcare Research
- Healthcare Education
- Healthcare Retail
- Technology-Enabled Healthcare Services
Investment Size:
10,000,000 to 150,000,000 USD
Investor Details Founded: 1989
OrbiMed Advisors LLC is a prominent healthcare investment firm based in New York City, specializing in public and private investments across the healthcare and biotechnology sectors. With over 25 years of experience, the firm manages approximately $19 billion in assets, investing globally through private equity funds, public equity funds, and royalty/credit funds. Their team comprises over 130 professionals operating from offices in New York, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and London.
The firm's investment strategy is comprehensive, targeting companies at various stages of development, from seed-stage startups to large multinational corporations. OrbiMed focuses on sectors such as biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They employ a flexible approach, investing in private equity, public equity, and private credit/royalty funds, aiming to provide tailored financing solutions and extensive global resources to build world-class healthcare companies.
OrbiMed has a notable track record, having backed over 110 life sciences startups and committed over $2 billion to developing-country healthcare initiatives. Their portfolio includes companies like ADARx Pharmaceuticals, Treeline Biosciences, Caris Life Sciences, and Biokin. The firm has also been active in raising substantial funds, such as the $1.86 billion raised for Healthcare Royalty & Credit Fund V in 2025, demonstrating strong investor confidence and a commitment to driving innovation in the healthcare sector.
Requirements
- Innovative and growth-oriented opportunities across healthcare sub-sectors
- Companies with strong management teams
- Potential for significant impact in the healthcare industry
- Alignment with OrbiMed's investment strategy and values
- Focus on healthcare and biotechnology sectors
- Investments across various stages from seed to buyout
- Global investment approach with a presence in multiple countries
- Commitment to responsible investing and ESG factors
- Companies in the healthcare and biotechnology sectors
- Global presence
- Various stages of development from seed-stage to large multinational corporations
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- ADARx Pharmaceuticals
- SpringWorks Therapeutics
- Treeline Biosciences
- Insilico Medicine
- Carrot Fertility
- DarioHealth
- MDClone
- TandemAI
- TytoCare
- CardiAQ
- AbCellera Biologics
- Acceleron Pharma
- Ambit Biosciences
- California Institute for Quantitative Biosciences
- Cynapsus Therapeutics
- DFINE, Inc.
- Gelesis
- Intercept Pharmaceuticals
- Natera
- OmniGuide
- TigerConnect
- Caris Life Sciences
- Biokin
- Avenzo Therapeutics
Mentioned In
-
$24.95
-
$24.95
-
$19.95
-
$9.95
-
$14.95
-
$39.95
-
$99.00
-
$299.00
-
$95.00
Claim this Investor
Are you an official representative of OrbiMed Advisors LLC?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim